ECVT & ECCT

Case: ECCT for Lung Adenocarcinoma with Positive EGFR Mutation.

A 30-year-old woman was diagnosed with lung cancer in October 2024. She initially complained of heavy, short-breathing and significant chest pain.A core biopsy and EGFR gene mutation screening revealed an adenocarcinoma type with a positive mutation. Her doctor prescribed gefitinib, a targeted therapy tablet, and she began using ECCT practically simultaneously.

The biopsy result indicates no tissue differentiation. The response of ECCT to adenocarcinoma cancer cell types is determined by the cells' electrical polarity, which correlates with their malignancy grade. For high-grade (high electrical polarity, e.g., undifferentiated adenocarcinoma), 70-80% of the tumor mass (independent of size) can be reduced in 1-3 months. The intermediate grade shrinks by 40-50% within 3-6 months. Low-grade (well-differentiated adenocarcinoma) requires 6-12 months to achieve a 20-30% decrease. Combining with targeted drug administration often improves the efficacy of the therapy while minimizing inflammation, especially when the mass volume is substantial.

Her response to the combination therapy was relatively positive and speedy. Her complaints of shortness of breath and soreness subsided within a month. The progress of ECCT treatment is generally determined by the smoothness of the excretion process. In her case, the majority of the elimination was through thick phlegm. Along with the smooth release of excessive and thick phlegm, her condition has improved, and her complaints have steadily lessened. The CT scan results after three months of use revealed a mass reduction of approximately 30-40% by volume. The response is consistent with a medium- to high-grade adenocarcinoma.

After 6 months of using the device, her symptoms have mostly vanished. She resumed her everyday routines as usual. The CT scan results suggest that the tumor mass has shrunk further, down to 50% of its original size. Her lungs retain some fluid, but her overall health and condition are just fine.

CASE: Low grade lung adenocarcinoma with ECCT combined with Chemotherapy

Low-grade adenocarcinoma often responses slowly to ECCT treatment. However, combining ECCT with chemotherapy after 2-3 months of use reveals a considerable reduction of 70-80% by volume in 6 months in a case of a 52-year-old male diagnosed with well-differentiated (low grade) adenocarcinoma with EGFR-negative mutation.